- Home
- BEAT vs KRON Comparison
BEAT vs KRON Comparison
Compare BEAT & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- KRON
- Stock Information
- Founded
- BEAT 2015
- KRON 2017
- Country
- BEAT United States
- KRON United States
- Employees
- BEAT N/A
- KRON N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- KRON Medicinal Chemicals and Botanical Products
- Sector
- BEAT Technology
- KRON Health Care
- Exchange
- BEAT Nasdaq
- KRON Nasdaq
- Market Cap
- BEAT 74.1M
- KRON 59.8M
- IPO Year
- BEAT 2021
- KRON 2020
- Fundamental
- Price
- BEAT $2.26
- KRON $0.99
- Analyst Decision
- BEAT Buy
- KRON Buy
- Analyst Count
- BEAT 1
- KRON 3
- Target Price
- BEAT $8.00
- KRON $1.63
- AVG Volume (30 Days)
- BEAT 110.4K
- KRON 231.8K
- Earning Date
- BEAT 03-19-2025
- KRON 03-20-2025
- Dividend Yield
- BEAT N/A
- KRON N/A
- EPS Growth
- BEAT N/A
- KRON N/A
- EPS
- BEAT N/A
- KRON N/A
- Revenue
- BEAT N/A
- KRON $9,864,000.00
- Revenue This Year
- BEAT N/A
- KRON $62.21
- Revenue Next Year
- BEAT N/A
- KRON N/A
- P/E Ratio
- BEAT N/A
- KRON N/A
- Revenue Growth
- BEAT N/A
- KRON 146.48
- 52 Week Low
- BEAT $1.35
- KRON $0.69
- 52 Week High
- BEAT $3.48
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- BEAT 47.78
- KRON 47.18
- Support Level
- BEAT $2.02
- KRON $0.99
- Resistance Level
- BEAT $2.44
- KRON $1.09
- Average True Range (ATR)
- BEAT 0.14
- KRON 0.05
- MACD
- BEAT 0.04
- KRON -0.00
- Stochastic Oscillator
- BEAT 50.00
- KRON 26.42
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.